NCT02354404View on ClinicalTrials.gov

Clinical Trial of Ebola Vaccines cAd3-EBO, cAd3-EBOZ and MVA-EbolaZ in Healthy Adults in Uganda

PHASE1CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

January 27, 2015

Primary Completion Date

April 19, 2017

Study Completion Date

April 19, 2017

Conditions
Hemorrhagic Fever, Ebola
Interventions
BIOLOGICAL

cAd3-EBOZ

cAd3 vaccine vector expressing Ebola glycoprotein from the Zaire strain in single dose vials at 1x10(11) PU/mL.

BIOLOGICAL

cAd3-EBO

1:1 ratio of cAd3 vaccine vectors expressing Ebola glycoprotein from the Zaire and Sudan strains filled into single dose vials at 1x10(11) PU/mL of each \[2x10(11) PU/mL total\].

BIOLOGICAL

MVA-EbolaZ

MVA vaccine vector that expresses Ebola glycoprotein from the Zaire strain in single dose vials at 3.2 x 10(8) PFU/mL

Trial Locations (1)

Unknown

Makerere University Walter Reed Project, Kampala

All Listed Sponsors
collaborator

US Military HIV Research Program

NETWORK

collaborator

The Emmes Company, LLC

INDUSTRY

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT02354404 - Clinical Trial of Ebola Vaccines cAd3-EBO, cAd3-EBOZ and MVA-EbolaZ in Healthy Adults in Uganda | Biotech Hunter | Biotech Hunter